[1]
|
Azim, H.A., Ghosn, M., Oualla, K., et al. (2020) Personalized Treatment in Metastatic Triple-Negative Breast Cancer: The Outlook in 2020. The Breast Journal, 26, 69-80. https://doi.org/10.1111/tbj.13713
|
[2]
|
Kumar, P. and Aggarwal, R. (2016) An Overview of Triple-Negative Breast Cancer. Archives of Gynecology and Obstetrics, 293, 247-269. https://doi.org/10.1007/s00404-015-3859-y
|
[3]
|
Da Silva, J.L., Cardoso Nunes, N.C., Izetti, P., et al. (2020) Triple Negative Breast Cancer: A Thorough Review of Biomarkers. Critical Reviews in Oncology/Hematology, 145, Article ID: 102855.
https://doi.org/10.1016/j.critrevonc.2019.102855
|
[4]
|
Yang, C.-Q., et al. (2020) Recent Treatment Progress of Triple Negative Breast Cancer. Progress in Biophysics and Molecular Biology, 151, 40-53. https://doi.org/10.1016/j.pbiomolbio.2019.11.007
|
[5]
|
Santuario-Facio, S.K., Cardona-Huerta, S., Perez-Paramo, Y.X., et al. (2017) A New Gene Expression Signature for Triple Negative Breast Cancer Using Frozen Fresh Tissue before Neoadjuvant Chemotherapy. Molecular Medicine, 23, 101-111. https://doi.org/10.2119/molmed.2016.00257
|
[6]
|
Abdel-Qadir, H., Austin, P.C., Lee, D.S., et al. (2017) A Population-Based Study of Cardiovascular Mortality Following Early-Stage Breast Cancer. JAMA Cardiology, 2, 88-93. https://doi.org/10.1001/jamacardio.2016.3841
|
[7]
|
Meijers, W.C. and De Boer, R.A. (2019) Common Risk Factors for Heart Failure and Cancer. Cardiovascular Research, 115, 844-853. https://doi.org/10.1093/cvr/cvz035
|
[8]
|
Dieli-Conwright, C.M., Wong, L., Waliany, S., et al. (2016) An Observational Study to Examine Changes in Metabolic Syndrome Components in Patients with Breast Cancer Receiving Neoadjuvant or Adjuvant Chemotherapy. Cancer, 122, 2646-2653. https://doi.org/10.1002/cncr.30104
|
[9]
|
Sharma, M., Tuaine, J., Mclaren, B., et al. (2016) Chemotherapy Agents Alter Plasma Lipids in Breast Cancer Patients and Show Differential Effects on Lipid Metabolism Genes in Liver Cells. PLoS ONE, 11, e0148049.
https://doi.org/10.1371/journal.pone.0148049
|
[10]
|
Srokowski, T.P., Fang, S., Hortobagyi, G.N., et al. (2009) Impact of Diabetes Mellitus on Complications and Outcomes of Adjuvant Chemotherapy in Older Patients with Breast Cancer. Journal of Clinical Oncology, 27, 2170-2176.
https://doi.org/10.1200/JCO.2008.17.5935
|
[11]
|
Giuliano, A.E., Connolly, J.L., Edge, S.B., et al. (2017) Breast Cancer-Major Changes in the American Joint Committee on Cancer Eighth Edition Cancer Staging Manual. CA: A Cancer Journal for Clinicians, 67, 290-303.
https://doi.org/10.3322/caac.21393
|
[12]
|
中国抗癌协会乳腺癌诊治指南与规范(2019年版) [J]. 中国癌症杂志, 2019, 29(8): 609-680.
|
[13]
|
池胜英, 袁谦, 陈筱菲, 等. 医院内快速血糖检测质量管理的实施[J]. 中华检验医学杂志, 2006, 29(6): 565-566.
|
[14]
|
向哲邑, 吴佳丽, 胡敏. 临床实验室的血脂检测与管理[J]. 中华检验医学杂志, 2017, 40(6): 421-424.
|
[15]
|
Ghoncheh, M., Pournamdar, Z. and Salehiniya, H. (2016) Incidence and Mortality and Epidemiology of Breast Cancer in the World. Asian Pacific Journal of Cancer Prevention: APJCP, 17, 43-46.
https://doi.org/10.7314/APJCP.2016.17.S3.43
|
[16]
|
师金, 梁迪, 李道娟, 等. 全球女性乳腺癌流行情况研究[J]. 中国肿瘤, 2017, 26(9): 683-690.
|
[17]
|
Gerdts, E. and Regitz-Zagrosek, V. (2019) Sex Differences in Cardiometabolic Disorders. Nature Medicine, 25, 1657-1666. https://doi.org/10.1038/s41591-019-0643-8
|
[18]
|
中国心血管健康与疾病报告2019概要[J]. 中国循环杂志, 2020, 35(9): 833-854.
|
[19]
|
Chase-Vilchez, A.Z., Chan, I.H.Y., Peters, S.A.E., et al. (2020) Diabetes as a Risk Factor for Incident Peripheral Arterial Disease in Women Compared to Men: A Systematic Review and Meta-Analysis. Cardiovascular Diabetology, 19, 151. https://doi.org/10.1186/s12933-020-01130-4
|
[20]
|
Zhang, X., Liu, J., Wang, M., et al. (2018) Twenty-Year Epidemiologic Study on LDL-C Levels in Relation to the Risks of Atherosclerotic Event, Hemorrhagic Stroke, and Cancer Death among Young and Middle-Aged Population in China. Journal of Clinical Lipidology, 12, 1179-1189e4. https://doi.org/10.1016/j.jacl.2018.06.011
|
[21]
|
Michels, N., De Backer, F., Dimakopoulou, M., et al. (2020) Eating Disorders and the Risk of Developing Cancer: A Systematic Review. Eating and Weight Disorders: EWD. https://doi.org/10.1007/s40519-020-01020-4
|
[22]
|
Chung, I.Y., Lee, J.W., Moon, H.G., et al. (2020) Effect of Standard Low-Dose Anthracycline Chemotherapy on Late Congestive Heart Failure in Breast Cancer Survivors Aged between 50 and 59 at Diagnosis: A Nationwide Study. Breast, 53, 125-129. https://doi.org/10.1016/j.breast.2020.07.006
|
[23]
|
Jacobse, J.N., Schaapveld, M., Boekel, N.B., et al. (2020) Risk of Heart Failure after Systemic Treatment for Early Breast Cancer: Results of a Cohort Study. Breast Cancer Research and Treatment.
https://doi.org/10.1007/s10549-020-05930-w
|
[24]
|
Cho, H., Lee, S., Sim, S.H., et al. (2020) Cumulative Incidence of Chemotherapy-Induced Cardiotoxicity during a 2-Year Follow-Up Period in Breast Cancer Patients. Breast Cancer Research and Treatment, 182, 333-343.
https://doi.org/10.1007/s10549-020-05703-5
|
[25]
|
Tian, W., Yao, Y., Fan, G., et al. (2019) Changes in Lipid Profiles during and after (neo)Adjuvant Chemotherapy in Women with Early-Stage Breast Cancer: A Retrospective Study. PLoS ONE, 14, e0221866.
https://doi.org/10.1371/journal.pone.0221866
|
[26]
|
Rader, D.J. and Hovingh, G.K. (2014) HDL and Cardiovascular Disease. The Lancet, 384, 618-625.
https://doi.org/10.1016/S0140-6736(14)61217-4
|
[27]
|
De Melo Gagliato, D., Buzaid, A.C., Perez-Garcia, J., et al. (2020) Immunotherapy in Breast Cancer: Current Practice and Clinical Challenges. BioDrugs: Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy, 34, 611-623.
https://doi.org/10.1007/s40259-020-00436-9
|
[28]
|
Mittendorf, E.A., Zhang, H., Barrios, C.H., et al. (2020) Neoadjuvant Atezolizumab in Combination with Sequential Nab-Paclitaxel and Anthracycline-Based Chemotherapy versus Placebo and Chemotherapy in Patients with Early-Stage Triple-Negative Breast Cancer (IMpassion031): A Randomised, Double-Blind, Phase 3 Trial. The Lancet, 396, 1090-1100. https://doi.org/10.1016/S0140-6736(20)31953-X
|
[29]
|
Schmid, P., Cortes, J., Pusztai, L., et al. (2020) Pembrolizumab for Early Triple-Negative Breast Cancer. The New England Journal of Medicine, 382, 810-821. https://doi.org/10.1056/NEJMoa1910549
|
[30]
|
Khan, S. and Gerber, D.E. (2020) Autoimmunity, Checkpoint Inhibitor Therapy and Immune-Related Adverse Events: A Review. Seminars in Cancer Biology, 64, 93-101. https://doi.org/10.1016/j.semcancer.2019.06.012
|